Background: More than half of patients with breast cancer were diagnosed with locally advanced stages of the disease (54%). This study aimed to explain the pathological response received with neoadjuvant chemotherapy (NACT) according to the molecular classi cation of breast cancer in patients with locally advanced tumors.Methods: One hundred one patients with locally advanced breast cancer treated with neoadjuvant chemotherapy were analyzed. Patients were classi ed into ve molecular subtypes based on the pro le of the estrogen receptor, progesterone receptor, HER2, and Ki-67. We determined associations between pathologic complete response and molecular subgroups.Results: Most patients had luminal A tumors (n:28, 27.7%). The overall rate of pathological complete response (pCR) was 34.7% (n:35). Tumors that presented the highest rate of pCR were pure HER2positive, at 60% (n:6; OR, 3.2; 95% CI, 0.8-12.2). According to logistic regression analysis, the factors affecting pCR were HER2 positivity and clinically positive axilla before NACT. Luminal A tumors had a signi cantly lower pCR rate. (7.1%,p: 0.001). Despite the low pCR rate, luminal A tumor survival was the best subgroup (p< 0.001). However, there was no difference between EFS and OS according to pCR in any molecular subgroups.Conclusion: Pathological complete response is directly related to the subtypes of breast cancer. A high rate of complete pathological response is observed in the pure HER2-positive group. However, EFS and OS were not statistically signi cant in patients with and without pCR.

This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kinase inhibitors (TKIs)between January 2007 and June 2020 (i.e., sunitinib, pazopanib) were included in this study. SII was calculated in 621 patients with the following formula:[neutrophil (cellsx109/L) x platelet (cellsx109/L)] / lymphocyte (cellsx109/L).All patients were classified into SII-high and SII-low groups based on the cut-off value of SII at 756, which was the median SII level of our study group. The minimal follow-up duration was 10 months in all cohorts. The median age of patients was 60 (interquartile range (IQR):53–67) years. Three out of four patients were male. The majority of patients (85.7%) had clear cell histology, and sarcomatoid differentiation was observed in 16.9% of all patients. There were 311 and 310 patients in the SII-low and SII-high groups, respectively. In general, baseline characteristics were similar in each group. However, the rate of patients treated with sunitinib (63.3% vs. 49.0%, p < 0.001) and those who underwent nephrectomy (83.6% vs. 64.2%, p < 0.001) was higher in the SII-low group than in the SII-high group. On the other hand, patients with the IMDC poorrisk (31.6% vs. 8.0%, p < 0.001), those with bone (51.8% vs. 32.2%, p < 0.001) or central nervous system (12.9% vs. 5.8%, p = 0.026) metastasis, and those with Eastern Cooperative Oncology Group(ECOG) 2–4 performance score (28.1% vs.17.7%, p = 0.002) were more common in the SII-high group than in the SII-low group. The median overall survival (OS) was longer in the SII-low group than in the SII-high group (34.6 months vs. 14.5 months, p < 0.001). Similarly, the median progression-free survival (PFS) was longer in the SII-low group than in the SII-high group (18.0 months vs. 7.7 months, p < 0.001).In multivariableanalysis, SII was an independent prognostic factor for OS (hazard ratio (HR):1.39, 95% confidence interval (CI):1.05–1.85, p = 0.01) and PFS (HR:1.60, 95% CI:1.24–2.05, p < 0.001).Pre-treatment level of high SII might be considered a predictor of poor prognosisin patients with mRCC treated with TKIs.

Undoubtedly, cancer patients have suffered the most from the COVID‐19 pandemic process. However, cancer is a heterogeneous disease, and each patient has responded differently to COVID‐19. We aimed to describe the clinical characteristics and outcomes of patients with cancer and COVID‐19. We retrospectively reviewed 45 cancer patients hospitalized in the Cerrahpaşa Medical Faculty COVID‐19 department from March 23 to October 23, 2020. We analyzed the demographic characteristics, symptoms, laboratory findings, treatment, prognosis, and cancer subtypes of patients and mortality who were hospitalized for COVID‐19. Between March 23 and October 23, 2020, 45 hospitalized cancer patients who had laboratory‐confirmed COVID‐19 infection were included, with a median age of 60 years (range: 23–92). Patients were divided into two groups a survivor and a non‐survivor. Symptoms, demographic information, comorbidities, treatments for COVID‐19, and laboratory findings of the two groups were evaluated separately. Two parameters were found, which showed a significant difference between non‐survivors and survivors displaying a disadvantage for COPD and low platelet count ( p = 0.044–0.038). The mortality rate of all patients was 66%. The presence of comorbidities such as COPD and low platelet count in cancer patients with COVID‐19 infection may draw the attention of physicians.

Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. Results: A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Conclusion: Nivolumab was effective in patients with mRCC and no new safety signal was observed.